(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
If the filing person has previously
filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“
Act
”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however,
see
the
Notes
).
|
|
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
2
of
13
Pages
|
|
|
|
|
|
1
|
NAMES OF REPORTING PERSONS
TPG Group Holdings (SBS) Advisors, Inc.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
CO
|
|
*
|
The calculation is based on 196,599,861 shares of common stock (“
Common Stock
”) of IQVIA Holdings Inc. (the
“
Issuer
”) outstanding as of February 12, 2019, as reported in the Prospectus Supplement filed by the Issuer
with the Securities and Exchange Commission (the “
Commission
”) on March 7, 2019, after giving effect to
the March 2019 Share Repurchase (as defined herein).
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
3
of
13
Pages
|
1
|
NAMES OF REPORTING PERSONS
TPG Advisors VI, Inc.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
CO
|
|
*
|
The calculation is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the
Prospectus Supplement filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share
Repurchase.
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
4
of
13
Pages
|
1
|
NAMES OF REPORTING PERSONS
TPG Advisors V, Inc.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
CO
|
|
*
|
The calculation is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the
Prospectus Supplement filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share
Repurchase.
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
5
of
13
Pages
|
1
|
NAMES OF REPORTING PERSONS
TPG Biotech Advisors, Inc.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
CO
|
|
*
|
The calculation is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the
Prospectus Supplement filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share
Repurchase.
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
6
of
13
Pages
|
1
|
NAMES OF REPORTING PERSONS
David Bonderman
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
IN
|
|
|
|
|
|
*
|
The calculation is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the
Prospectus Supplement filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share
Repurchase.
|
CUSIP No.
46266C105
|
SCHEDULE 13D
|
Page
7
of
13
Pages
|
.
1
|
NAMES OF REPORTING PERSONS
James G. Coulter
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
OO (See Item 3)
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
|
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
- 0 -
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
8,531,251 (See Items 3, 4 and 5)
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
8,531,251 (See Items 3, 4 and 5)
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,531,251 (See Items 3, 4 and 5)
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3% (See Item 5)*
|
14
|
TYPE OF REPORTING PERSON
IN
|
|
|
|
|
|
*
|
The calculation is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the
Prospectus Supplement filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share
Repurchase.
|
This Amendment No. 8 (the “
Amendment
”)
amends and supplements the Schedule 13D filed by the Reporting Persons on October 13, 2016, as amended and supplemented by
Amendment No. 1 filed on March 2, 2017, Amendment No. 2 filed on June 2, 2017, Amendment No. 3 filed on
August 30, 2017, Amendment No. 4 filed on September 21, 2017, Amendment No. 5 filed on December 4, 2017,
Amendment No. 6 filed on June 19, 2018 and Amendment No. 7 filed on December 6, 2018 (as so amended, the “
Original
Schedule 13D
” and, as amended and supplemented by this Amendment, the “
Schedule 13D
”), with respect
to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings
ascribed to them in the Original Schedule 13D.
Item 2.
Identity and Background
.
This Amendment amends and restates the
second paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:
“Group Advisors is the sole member
of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings
(SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company,
which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of each of (i) TPG
GenPar V Advisors, LLC, a Delaware limited liability company, (ii) TPG GenPar VI Advisors, LLC, a Delaware limited liability company,
and (iii) TPG Biotechnology GenPar III Advisors, LLC, a Delaware limited liability company. TPG GenPar V Advisors, LLC is the general
partner of TPG GenPar V, L.P., a Delaware limited partnership, which is the general partner of each of (i) TPG Partners V,
L.P., a Delaware limited partnership, which directly holds 3,050,771 shares of Common Stock, (ii) TPG FOF V-A, L.P., a Delaware
limited partnership, which directly holds 7,981 shares of Common Stock, and (iii) TPG FOF V-B, L.P., a Delaware limited partnership,
which directly holds 6,435 shares of Common Stock. TPG GenPar VI Advisors, LLC is the general partner of TPG GenPar VI, L.P., a
Delaware limited partnership, which is the general partner of TPG Partners VI, L.P., a Delaware limited partnership, which directly
holds 3,053,120 shares of Common Stock. TPG Biotechnology GenPar III Advisors, LLC is the general partner of TPG Biotechnology
GenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners III, L.P., a Delaware
limited partnership, which directly holds 125,967 shares of Common Stock. Advisors VI is the (i) general partner of TPG FOF
VI SPV, L.P., a Delaware limited partnership, which directly holds 12,069 shares of Common Stock, and (ii) managing member
of TPG Iceberg Co-Invest LLC, a Delaware limited liability company, which directly holds 1,049,722 shares of Common Stock. Advisors
V is the general partner of TPG Quintiles Holdco II, L.P., a Delaware limited partnership, which directly holds 1,164,263 shares
of Common Stock. Biotech Advisors is the general partner of TPG Quintiles Holdco III, L.P., a Delaware limited partnership (together
with TPG Partners V, L.P., TPG FOF V-A, L.P., TPG FOF V-B, L.P., TPG Partners VI, L.P., TPG Biotechnology Partners III, L.P., TPG
FOF VI SPV, L.P., TPG Iceberg Co-Invest LLC and TPG Quintiles Holdco II, L.P., the “
TPG Funds
”), which directly
holds 60,923 shares of Common Stock.”
Item 4.
Purpose of Transaction
.
This Amendment amends and restates the
final two paragraphs of Item 4 of the Original Schedule 13D in their entirety as set forth below:
“
March 2019 Registered
Offering
On March 5, 2019, the TPG Funds
entered into an underwriting agreement (the “
March 2019 Underwriting Agreement
”), with the Issuer, the other
selling stockholders named in Schedule I thereto (such selling stockholders, together with the TPG Funds, the “
March 2019
Selling Stockholders
”) and Goldman Sachs & Co. LLC and Barclays Capital Inc., as underwriters (the “
March
2019 Underwriter
”), pursuant to which the TPG Funds agreed to sell 4,044,480 shares of Common Stock at a price of $140.80
per share (the “
March 2019 Registered Offering
”). The Issuer agreed to purchase from the March 2019 Underwriters
1,000,000 of the 5,000,000 shares of Common Stock that were the subject of the March 2019 Registered Offering at a price of $140.80
per share (the “
March 2019 Share Repurchase
”). The March 2019 Registered Offering and the March 2019 Share Repurchase
closed on March 8, 2019.
March 2019 Lock-Up Agreement
In connection with the March 2019 Registered
Offering, the March 2019 Selling Stockholders, including each TPG Fund, agreed with the March 2019 Underwriters, pursuant to a
lock-up agreement (each, a “
March 2019 Lock-Up Agreement
”), that they will not offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any other securities
so owned convertible or exercisable or exchangeable for shares of Common Stock (other than as contemplated by the March 2019 Underwriting
Agreement or pursuant to certain other exceptions), without the prior written consent of Goldman Sachs & Co. LLC, for a period
of 30 days after the date of the March 2019 Underwriting Agreement.
Other than as described above, none of
the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, without independent verification, any of the
persons listed in Schedules I, II, III and IV hereto, currently has any plans or proposals that relate to, or would result in,
any of the matters listed in Items 4(a)–(j) of Schedule 13D, although the Reporting Persons may, at any time and from time
to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.
As a result of these activities, one or more of the Reporting Persons may suggest or take a position with respect to potential
changes in the operations, management or capital structure of the Issuer as a means of enhancing shareholder value. Such suggestions
or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported
herein, including, without limitation, such matters as acquiring additional securities of the Issuer or disposing of securities
of the Issuer; entering into an extraordinary corporate transaction such as a merger, reorganization or liquidation, involving
the Issuer or any of its subsidiaries; selling or transferring a material amount of assets of the Issuer or any of its subsidiaries;
changing the present board of directors or management of the Issuer, including changing the number or term of directors or filling
any existing vacancies on the board of directors of the Issuer; materially changing the present capitalization or dividend policy
of the Issuer; materially changing the Issuer’s business or corporate structure; changing the Issuer’s certificate
of incorporation, bylaws or instruments corresponding thereto or taking other actions which may impede the acquisition of control
of the Issuer by any person; causing a class of securities of the Issuer to be delisted from a national securities exchange or
to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; causing
a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the
Securities Act of 1933, as amended; and taking any action similar to any of those enumerated above.
References to and the descriptions of
the Shareholders Agreement, March 2017 Share Repurchase Agreement, May 2017 Underwriting Agreement, May 2017 Lock-Up Agreement,
September 2017 Underwriting Agreement, September 2017 Lock-Up Agreement, November 2017 Underwriting Agreement, November 2017 Lock-Up
Agreement, June 2018 Underwriting Agreement, June 2018 Lock-Up Agreement, November 2018 Underwriting Agreement, November 2018 Lock-Up
Agreement, March 2019 Underwriting Agreement and March 2019 Lock-Up Agreement set forth above are not intended to be complete and
are qualified, respectively, in their entirety by reference to the full text of the Shareholders Agreement, March 2017 Share Repurchase
Agreement, May 2017 Underwriting Agreement, May 2017 Lock-Up Agreement, September 2017 Underwriting Agreement, September 2017 Lock-Up
Agreement, November 2017 Underwriting Agreement, November 2017 Lock-Up Agreement, June 2018 Underwriting Agreement, June 2018 Lock-Up
Agreement, November 2018 Underwriting Agreement, November 2018 Lock-Up Agreement, March 2019 Underwriting Agreement and March 2019
Lock-Up Agreement, which are filed as exhibits hereto and are incorporated by reference herein.”
Item 5.
Interest in Securities of the Issuer
.
This Amendment amends and restates the
second and third paragraphs of Item 5 of the Original Schedule 13D in their entirety as set forth below:
“(a)-(b) The following sentence
is based on 196,599,861 shares of Common Stock outstanding as of February 12, 2019, as reported in the Prospectus Supplement
filed by the Issuer with the Commission on March 7, 2019, after giving effect to the March 2019 Share Repurchase. Pursuant
to Rule 13d-3 under the Act, the Reporting Persons may be deemed to beneficially own 8,531,251 shares of Common Stock, which constitutes
approximately 4.3% of the outstanding shares of Common Stock.”
This Amendment amends and restates the
sixth paragraph of Item 5 of the Original Schedule 13D in its entirety as set forth below:
“(e) As a result of the March
2019 Registered Offering, on March 8, 2019 the Reporting Persons ceased to be the beneficial owner of more than five percent
of the shares of Common Stock.”
Item 7.
Material to be Filed as Exhibits
.
This Amendment amends and supplements
Item 7 of the Original Schedule 13D by adding the following:
“15. Underwriting Agreement,
dated March 5, 2019 by and among IQVIA Holdings Inc., the selling stockholders listed in Schedule I thereto and Goldman Sachs
& Co. LLC and Barclays Capital Inc. (incorporated by reference to Exhibit 1.1 to the Issuer’s Current Report on Form
8-K filed with the Commission on March 8, 2019).
|
16.
|
Form of Lock-Up Letter, dated March 5, 2019, by and among each of the selling stockholders listed in Schedule I to the
Underwriting Agreement and Goldman Sachs & Co. LLC and Barclays Capital Inc. (incorporated by reference to Exhibit A to Exhibit
1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on March 8, 2019).”
|
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 12, 2019
TPG Group Holdings (SBS) Advisors,
Inc.
By:
/s/ Michael LaGatta
Name: Michael LaGatta
Title: Vice President
TPG Advisors VI, Inc.
By:
/s/ Michael LaGatta
Name: Michael LaGatta
Title: Vice President
TPG Advisors V, Inc.
By:
/s/ Michael LaGatta
Name: Michael LaGatta
Title: Vice President
TPG Biotech Advisors, Inc.
By:
/s/ Michael LaGatta
Name: Michael LaGatta
Title: Vice President
David Bonderman
By:
/s/ Bradford Berenson
Name: Bradford Berenson, on behalf
of David Bonderman (1)
James G. Coulter
By:
/s/ Bradford Berenson
Name: Bradford Berenson, on behalf
of James G. Coulter (2)
(1) Bradford Berenson is signing on behalf of Mr. Bonderman pursuant
to an authorization and designation letter dated March 13, 2018, which was previously filed with the Commission as an exhibit
to a Schedule 13G filed by Mr. Bonderman on April 2, 2018 (SEC File No. 005-90172).
(2) Bradford Berenson is signing on behalf of Mr. Coulter pursuant
to an authorization and designation letter dated March 13, 2018, which was previously filed with the Commission as an exhibit
to a Schedule 13G filed by Mr. Coulter on April 2, 2018 (SEC File No. 005-90172).
INDEX TO EXHIBITS
|
1.
|
Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG Advisors VI, Inc.,
TPG Advisors V, Inc., TPG Biotech Advisors, Inc., David Bonderman and James G. Coulter, dated as of October 13, 2016 (incorporated
by reference to Exhibit 1 to Schedule 13D filed with the Commission on October 13, 2016 by TPG Group Holdings (SBS) Advisors, Inc.,
TPG Advisors VI, Inc., TPG Advisors V, Inc., TPG Biotech Advisors, Inc., David Bonderman and James G. Coulter).
|
|
2.
|
Agreement and Plan of Merger, dated as of May 3, 2016, by and among the IMS Health Holdings,
Inc. and Quintiles Transnational Holdings Inc. (incorporated herein by reference to Exhibit 2.1 to the Issuer’s Current Report
on Form 8-K filed with the Commission on May 3, 2016).
|
|
3.
|
Shareholders Agreement, dated as of May 3, 2016, by and among Quintiles Transnational Holdings
Inc. and Certain Shareholders (incorporated herein by reference to Exhibit 10.4 to the Issuer’s Current Report on Form 8-K
filed with the Commission on May 3, 2016).
|
|
4.
|
Share Repurchase Agreement, dates as of February 23, 2017, by and among Quintiles IMS Holdings,
Inc. and the selling shareholders set forth in Schedule I thereto (incorporated herein by reference to Exhibit 10.1 to the Issuer’s
Current Report on Form 8-K filed with the Commission on February 24, 2017).
|
|
5.
|
Underwriting Agreement, dated May 24, 2017 by and among Quintiles IMS Holdings, Inc., the selling
stockholders listed in Schedule I thereto and Morgan Stanley & Co. LLC (incorporated by reference to Exhibit 1.1 to the Issuer’s
Current Report on Form 8-K filed with the Commission on May 31, 2017).
|
|
6.
|
Form of Lock-Up Letter, dated May 24, 2017, by and among each of the selling stockholders listed
in Schedule I to the Underwriting Agreement and Morgan Stanley & Co. LLC (incorporated by reference to Exhibit A to Exhibit
1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on May 31, 2017).
|
|
7.
|
Underwriting Agreement, dated September 14, 2017 by and among Quintiles IMS Holdings, Inc., the
selling stockholders listed in Schedule I thereto and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit 1.1 to
the Issuer’s Current Report on Form 8-K filed with the Commission on September 19, 2017).
|
|
8.
|
Form of Lock-Up Letter, dated September 14, 2017, by and among each of the selling stockholders
listed in Schedule I to the Underwriting Agreement and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit A to Exhibit
1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on September 19, 2017).
|
|
9.
|
Underwriting Agreement, dated November 27, 2017 by and among IQVIA Holdings Inc., the selling
stockholders listed in Schedule I thereto and Morgan Stanley & Co. LLC (incorporated by reference to Exhibit 1.1 to the Issuer’s
Current Report on Form 8-K filed with the Commission on November 30, 2017).
|
|
10.
|
Form of Lock-Up Letter, dated November 27, 2017, by and among each of the selling stockholders
listed in Schedule I to the Underwriting Agreement and Morgan Stanley & Co. LLC (incorporated by reference to Exhibit A to
Exhibit 1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on November 30, 2017).
|
|
11.
|
Underwriting Agreement, dated June 12, 2018 by and among IQVIA Holdings Inc., the selling
stockholders listed in Schedule I thereto and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit 1.1 to the Issuer’s
Current Report on Form 8-K filed with the Commission on June 15, 2018).
|
|
12.
|
Form of Lock-Up Letter, dated June 12, 2018, by and among each of the selling stockholders
listed in Schedule I to the Underwriting Agreement and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit A to Exhibit
1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on June 15, 2018).
|
|
13.
|
Underwriting Agreement, dated November 29, 2018 by and among IQVIA Holdings Inc., the selling
stockholders listed in Schedule I thereto and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit 1.1 to the Issuer’s
Current Report on Form 8-K filed with the Commission on December 4, 2018).
|
|
14.
|
Form of Lock-Up Letter, dated November 29, 2018, by and among each of the selling stockholders
listed in Schedule I to the Underwriting Agreement and Goldman Sachs & Co. LLC (incorporated by reference to Exhibit A to Exhibit
1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on December 4, 2018).
|
|
15.
|
Underwriting Agreement, dated March 5, 2019 by and among IQVIA Holdings Inc., the selling
stockholders listed in Schedule I thereto and Goldman Sachs & Co. LLC and Barclays Capital Inc. (incorporated by reference
to Exhibit 1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on March 8, 2019).
|
|
16.
|
Form of Lock-Up Letter, dated March 5, 2019, by and among each of the selling stockholders
listed in Schedule I to the Underwriting Agreement and Goldman Sachs & Co. LLC and Barclays Capital Inc. (incorporated by reference
to Exhibit A to Exhibit 1.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on March 8, 2019).
|